• Roche Challenger to Biogen's SMA Drug Succeeds in Pivotal Study

    1 month ago - By Xconomy

    A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder. Roche announced Monday that its drug, risdiplam, met the main goal of showing improvement according to a scale used to assess motor function, compared to a placebo, after one year of treatment. The Basel, Switzerland-based company plans to present full data from the study at a future medical conference. Spinal muscular atrophy is caused by a genetic defect in the SMN1...
    Read more ...